The Glucoday Monitor
THE GLUCODAY DIABETIC MONITORING DEVICE.
INTRODUCTION
The GlucoDay® Diabetic monitoring device is used to continuously monitor blood glucose level all day long. Patients using invasive self-monitoring devices assess blood glucose irregularly because of the associated pain and inability to carry out measurement at night while they are sleeping (Boland et al., 2001; Maran et al., 2002). Precise and accurate continuous monitoring of blood glucose level using the GlucoDay® device is however of immense benefit to the patient as it provides an indication of the impact of medications, food intake, exercise, stress and other lifestyle factors on blood glucose profile; this is further enhanced by the in-built alarm system that alerts the patient of extreme glucose values in both low and high directions (Maran et al., 2002; Skyler, 2009).
An efficient continuous monitoring of blood glucose is therefore an important part of a successful diabetes management programme; it provides patient’s blood glucose level in real time and promotes appropriate insulin dosing or administration and appropriate lifestyle modification (Sieg et al., 2004). This is a desirable situation that can help to reduce long-term impact of diabetes on individuals as confirmed by the Diabetes Control and Complications Trial Group in 1993.
DEVICE DESIGN AND PRINCIPLES
The GlucoDay® Diabetic monitoring unit produced by A. Menarini Diadnostics, Italy is a minimally or semi-invasive portable device contained in a pouch that is worn with a belt round the waist of a patient; it is basically made up of a biosensor and a micropump connected to a microdialysis system inserted subcutaneously to the abdominal (periumbilical) region of the patient (Maran and Poscia, 2002; Maran et al., 2002; Skyler, 2009). The device once calibrated, powered by 9 volts battery measures and records subcutaneous glucose level every three (3) minutes which is displayed, stored and later downloaded on a computer (Maran and
INTRODUCTION
The GlucoDay® Diabetic monitoring device is used to continuously monitor blood glucose level all day long. Patients using invasive self-monitoring devices assess blood glucose irregularly because of the associated pain and inability to carry out measurement at night while they are sleeping (Boland et al., 2001; Maran et al., 2002). Precise and accurate continuous monitoring of blood glucose level using the GlucoDay® device is however of immense benefit to the patient as it provides an indication of the impact of medications, food intake, exercise, stress and other lifestyle factors on blood glucose profile; this is further enhanced by the in-built alarm system that alerts the patient of extreme glucose values in both low and high directions (Maran et al., 2002; Skyler, 2009).
An efficient continuous monitoring of blood glucose is therefore an important part of a successful diabetes management programme; it provides patient’s blood glucose level in real time and promotes appropriate insulin dosing or administration and appropriate lifestyle modification (Sieg et al., 2004). This is a desirable situation that can help to reduce long-term impact of diabetes on individuals as confirmed by the Diabetes Control and Complications Trial Group in 1993.
DEVICE DESIGN AND PRINCIPLES
The GlucoDay® Diabetic monitoring unit produced by A. Menarini Diadnostics, Italy is a minimally or semi-invasive portable device contained in a pouch that is worn with a belt round the waist of a patient; it is basically made up of a biosensor and a micropump connected to a microdialysis system inserted subcutaneously to the abdominal (periumbilical) region of the patient (Maran and Poscia, 2002; Maran et al., 2002; Skyler, 2009). The device once calibrated, powered by 9 volts battery measures and records subcutaneous glucose level every three (3) minutes which is displayed, stored and later downloaded on a computer (Maran and
References: Caifeng, N., Zhang, Y., Zhang, G., Dong, C., Shaomin, S. and Choi, M. F. (2009). Activation of nylon net and its application to a biosensor for determination of glucose in human serum. Enzyme and Microbial Technology 5, 249-253. Cengiz, E. and Tamborlane, W. V. (2009). A tale of two compartments: Interstitial versus blood glucose monitoring. Diabetes Technology and Therapeutics 11, 11-16. Chaplin, M. F. (2009). Biosensors. In molecular biology and biotechnology (ed. J. M. Walker and R. Rapley), pp 513-549. Cambridge: RSC Publishing. The Diabetes Control and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986. Flanagan, D. (2009). The future of glucose sensors – using the technology within a clinical service. Diabetic Medicine 26, 195-196. Joseph, J. I., Hipszer, B., Mraovic, B., Chervoneva, I., Joseph, M. and Grunwald, Z. (2009). Clinical need for continuous glucose monitoring in the hospital. J. Diabetes Sci. Technol. 3, 1309-1318. Maran, A. and Poscia, A. (2002). Continuous subcutaneous glucose monitoring: the GlucoDay® system. Diab. Nutr. Metab. 15, 429-433. Maran, A., Crepaldi, C., Tiengo, A., Grassi, G., Vitali, E., Pagano, G., Bistoni, S., Calabrese, G., Santeusanio, F., Leonetti, F. et al. (2002). Continuous glucose monitoring in diabetic patients. A multicentre analysis. Diabetes Care 25, 347-352. Oliver, N. S., Toumazou, C., Cass, A. E. G. and Johnston, D. G. (2009). Glucose sensors: a review of current and emerging technology. Diabetic Medicine 26, 197-210. Sieg, A., Guy, R. H. and Delgado-charro, M. B. (2004). Non-invasive glucose monitoring by reverse iontophoresis in vivo application of the internal standard concept. Clinical Chemistry 50, 1383-1390. Skyler, J. S. (2009). Continuous glucose monitoring: an overview of its development. Diabetes Technology and Therapeutics 11, 5-10.